Predictors for chemotherapy-related severe or febrile neutropenia: A review of the clinical literature

Journal of Oncology Pharmacy Practice

Volumn 7, Issue 4, 2001, Pages 141-147

  Wilson Royalty, Michele ^a  

^a AMGEN INC   (United States)

Author keywords

G CSF; Neutropenia; Predictors; Risk factors; Treatment guidelines

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; VINCRISTINE;

ADULT; AGE; ALGORITHM; ARTICLE; BLOOD CELL COUNT; BONE MARROW METASTASIS; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; HEMATOPOIETIC CELL; HUMAN; MEDICAL LITERATURE; NEUTROPHIL; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE;

EID: 0035557286     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155201jp084oa     Document Type: Article

References (37)

1. A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care
2. Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: An evidence-based review
3. Predicting risk of neutropenic complications: A point-of-care assessment tool
4. Clinical prediction models for febrile neutropenia (FN) and relative dose intensity (RDI) in patients receiving adjuvant breast cancer chemotherapy
5. Update of the economic analyses of the colony-stimulating factors
6. Adjuvant cyclophosphamide, methotrexate, and fluorouricil in node positive breast cancer
7. Management of the cancer patient with fever and prolonged neutropenia
8. Neutropenic complications in advanced stage non-Hodgkin's lymphoma: Implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF)
9. Optimal scheduling of granulocyte macrophage stimulating factor (GM-CSF) for the abrogation of chemotherapy-induced neutropenia in small cell lung cancer
10. Filgrastim (r-metHuG-CSF): The first 10 years
11. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
12. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
13. Development and validation of a patient-specific predictive instrument for the need for dose-reduction in chemotherapy for breast cancer: A potential decision aid for the use of myeloid growth factors
14. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
15. Factors predicting for efficacy and safety of docetaxel in a compassionate use cohort of 825 heavily pre-treated advanced breast cancer patients
16. Prognostic significance of febrile episodes in lung cancer patients receiving chemotherapy
17. The predictive value of body protein for chemotherapy-induced toxicity
18. Determinants of myelosuppression in the treatment of non-small cell lung cancer with cisplatin-containing chemotherapy
19. Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B)
20. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial
21. Carboplatin containing regimens for small cell lung cancer: Implications for management in the elderly
22. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: A Southwest Oncology Group study
23. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: A risk factor analysis
24. Prognostic factors for tumor response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second line chemotherapy therapy after 5-FU failure
25. Early lymphoma after cytotoxic chemotherapy as a risk factor for febrile neutropenia
26. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma
27. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: Role of the tumor necrosis factor ligand-receptor system
28. Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapy
29. Early monocytopenia after chemotherapy as a risk factor for neutropenia
30. Predicting neutropenia after chemotherapy for lymphoma
31. First-cycle counts and subsequent neutropenia, dose reduction, or delay in early stage breast cancer therapy
32. Surveillance of colony-stimulating factor use in US academic health centers
33. The impact of therapy with recombinant granulocyte colony stimulating factor (G-CSF) on the health care costs associated with cancer chemotherapy
34. A prospective trial assessing a risk model for filgrastim use on chemotherapy (CT) dose intensity (DI) in the adjuvant treatment of stage I-III breast cancer patients (BCP)
35. Long-term results of a multicentre randomized, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas
36. Bone marrow involvement, in intensively treated patients with intermediate grade non-Hodgkin's lymphoma, is a risk factor for granulocytopenia and fever
37. The epidemiology and economics of neutropenia in hospitalized cancer patients: Data from the University Health System Consortium